An2 Therapeutics extends funding for tuberculosis research collaboration with GSK
The Gates Foundation funding supports advancement of boron-based LeuRS inhibitors for TB treatment.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
AN2 Therapeutics extends Gates Foundation funding for TB research with GSK
The company said the Gates Foundation awarded an extension of funding to support its ongoing tuberculosis research collaboration with GSK. The work focuses on boron-based leucyl-tRNA synthetase inhibitors.
AN2 Therapeutics extends tuberculosis research funding collaboration with GSK
AN2 Therapeutics said it extended funding for its tuberculosis research collaboration with GSK.
AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK
AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical stage pharmaceutical company focused on the discovery and development of small molecule therapeutics derived from its boron chemistry platform, today announced that the Gates Foundation has awarded an extension of funding to support AN2 Therapeutics'…